Events

Pro-COAG 2022

Venous thromboembolism risk and anticoagulation in special populations

Pro-COAG is a scientific and educational event, with top experts in the area of Coagulation, sharing their knowledge on current hot topics. Stay up-to-date on the latest global trends and most significant developments. 

 

The pro-COAG meeting covers topics of interest for laboratories, clinicians and healthcare institutions to facilitate shaping future pathways in the field of Coagulation and to identify unmet medical needs. We strive to empower clinicians to improve patient care and treatment and serve as an opportunity for discussions and exchange of expert opinions. 

 

This year, the pro-COAG will be held virtually for the second time and we are looking forward to offering you a deep dive into Coagulation. Our exciting scientific program includes presentations and a panel discussion focusing on the risk of venous thromboembolism (VTE) in special populations, such as pregnant women and women on hormone therapy, hospitalised and cancer patients.

 

Join us, expand your knowledge and exchange opinions and experiences with other lab experts and clinicians around the globe.

Agenda

Tuesday 17th of May 2022

9:00 - 10:30 CEST /

15:00 - 16:30 SGT

 

 

Venous thromboembolism (VTE) risk and anticoagulation in special populations

9:00 - 9:05 CEST/ 15:00 - 15:05 SGT

Welcome and Introduction

Prof. Pantep Angchaisuksiri

 

9:05 - 9:25 CEST/ 15:05 - 15:25 SGT

Risk and management of VTE in pregnancy and hormone therapy in women

Prof. Lai Heng Lee

 

9:25 - 9:45 CEST/ 15:25 - 15:45 SGT

Thrombosis risk and anticoagulation in hospitalised patients

Prof. Alex C. Spyropoulos

 

9:45 - 10:05 CEST/ 15:45 - 16:05 SGT

Thrombosis in inflammation and cancer

Prof. Heng Joo Ng

 

10:05 - 10:25 CEST/ 16:05 - 16:25 SGT

Panel discussion: Importance of coagulation testing in clinical practices, with focus on special populations

All speakers

 

10:25 - 10:30 CEST/ 16:25 - 16:30 SGT

Session close

Prof. Pantep Angchaisuksiri

Meet the speakers

Pantep Angchaisuksiri, M.D.
Pantep Angchaisuksiri
 

MD

 

Pantep Angchaisuksiri, M.D., is Professor of Medicine and Chief of the Hemostasis and Thrombosis Unit in the Division of Hematology, Department of Medicine, at Ramathibodi Hospital, Mahidol University in Bangkok, Thailand. He also holds posts of Adjunct Associate Professor of Medicine at the University of North Carolina at Chapel Hill, School of Medicine, USA. An active clinician, Professor Angchaisuksiri works with patients with thrombosis, and bleeding disorders. He is a council member of the International Society on Thrombosis and Haemostasis (ISTH) and the Asian-Pacific Society on Thrombosis and Hemostasis (APSTH). He is also ISTH President for the 2024-2026 term, and chair of the ISTH Education and Outreach Committee.

Lee Lai Heng
Lai Heng Lee
 

MBBS, MMed, FRCP(Edin), FAMS

 

Prof. Lee received her medical and advanced specialist training in haematology in Singapore. She is previously head and currently a senior consultant with the Department of Haematology at Singapore General Hospital. Her keen interest in coagulation disorders resulted in numerous publications and she played a key role in clinical trials in novel anticoagulants in Singapore and the Asia Pacific. She was instrumental in the setting up of the anticoagulation clinic, promoting patient safety in anticoagulation therapy and developing the subspecialty of Thrombosis and Haemostasis in Singapore.  A/Prof. Lee is also actively involved in medical education in her roles as Clinical Associate Professor Yong Loo Lin School of Medicine, NUS and Adjunct Associate Professor, Duke-NUS Graduate Medical School. Besides her clinical, research, administrative and academic duties, A/Prof. Lee also participates actively in the local and regional professional scenes as Chairman of the Asia-Pacific Society for Thrombosis and Haemostasis, Chairman of the Chapter of Haematology, Council Member of the College of Physician, Singapore and as past President of the Singapore Society of Haematology.

Alex C. Spyropoulos
Alex C. Spyropoulos
 

MD, FACP, FCCP, FRCPC

 

Prof. Spyropoulos was Founder and former Medical Director of the Clinical Thrombosis Center in Albuquerque, New Mexico. He is a Professor of Medicine at the Zucker School of Medicine at Hofstra/Northwell System Director of Anticoagulation and Clinical Thrombosis Services for the multi hospital Northwell Health System in NY. He is also a Professor of the Center for Health Innovations and Outcomes Research/Institute for Health Systems Science as part of the Feinstein Institute for Medical Research. He is co-chair of the Council on Leadership of Thrombosis at Northwell Health System. He is a Fellow of the American College of Physicians, American College of Chest Physicians, International Academy of Clinical and Applied Thrombosis/Haemostasis, and the Royal College of Physicians, Canada.

Ng Heng Joo
Heng Joo Ng
 

MBBS, MMed (Int Med), MRCP (UK), FRCPath (UK), FAMS

Prof. Ng is currently senior consultant and Head of the Department of Haematology, Singapore General Hospital (SGH). He is a Clinical Professor with the Duke-National University of Singapore (NUS) School of Medicine, senior lecturer with the Yong Loo Lin School of Medicine, NUS. After graduating from NUS in 1993, Prof. Ng practiced in the Malaysian state of Sarawak before training in Haematology at SGH. He attained specialist accreditation in 2004 and thereafter did a year-long fellowship in thrombosis and haemostasis at McMaster University in Hamilton, Canada. His research interest is in optimisation of anticoagulation and bleeding disorders. 

Register

Join pro-COAG 2022

Form Successfully Submitted!
Thank you for your submission!
text

Highlights from previous pro-COAG events

 

Looking back

Scientific Program

 

Virtual pro-COAG 2021 topics

Addressing diagnostic challenges in coagulation during COVID-19 and beyond
  • Sepsis and endotheliitis: profound impact on coagulation and thrombosis
  • Thrombosis, Cancer and COVID-19
  • Vitamin K deficiency as the potential missing link between lung damage and thromboembolism in COVID-19
  • Anticoagulation for the prevention of COVID-19-associated thrombosis
Steve Kitchen

Steve Kitchen

PhD, FIBMS

 

Steve Kitchen is lead scientist at the coagulation laboratory of the Sheffield Haemophilia and Thrombosis Centre, which is part of the Sheffield teaching hospitals and designated as an International Haemophilia Training Centre by the World Federation of Haemophilia. In addition, he is the Scientific Director of the UK National External Quality Assessment Scheme for Blood Coagulation and Director of the WFH International External Quality Assessment Schemes for Blood Coagulation. Steve is also on the Steering committee UK NEQAS Blood Coagulation, part of the World Federation of Haemophilia, SSC Working Group on Diagnostic Standards and vice chair for Haemostasis at the ICSH.

Marcel Levi

Prof. Marcel Levi

MD PhD FRCP

 

Marcel Levi is Professor of Medicine at University College London Hospitals UCL and a practicing physician in Acute Medicine and Haematology. Previously he was Dean of the Faculty of Medicine of the University of Amsterdam and Chief Executive of the Academic Medical Center in Amsterdam. He has published more than 700 articles in scientific journals and has been awarded a number of international research awards. He was chairman of the Netherlands Organization for Health Research and is currently chairman of the scientific board of several national charities, including the Dutch Heart Foundation, and a board member of the National Cancer Institute. He is a member of the Royal Netherlands Academy of Science and Fellow of the Royal College of Physicians.

Anna Falanga

Anna Falanga

MD, Professor of Hematology

 

Anna Falanga, MD, is full professor of Hematology at University of Milan Bicocca and Chief of the Department of Immunohematology and Transfusion Medicine and the Thrombosis and Hemostasis Center, at the Hospital Papa Giovanni XXIII, in Bergamo, Italy. She has authored more than 300 publications and is guest editor of 21 volumes. She is an expert in the field of cancer and thrombosis. She has an active role in several professional societies, including the International Society of Thrombosis and Haemostasis (ISTH), the European Hematology Association (EHA), the Italian Society of Thrombosis and Hemostasis (SISET). She received the BACH Investigator Award of the ISTH (2009), and the “Harold R. Roberts Medal 2015” of the SSC of ISTH (2015).

Rob Janssen

Dr. Rob Janssen

Dr.

 

Rob Janssen is a pulmonologist in the Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands since 2008. He was trained as a pulmonologist in the St Antonius Hospital, Nieuwegein, The Netherlands and studied medicine in Utrecht, The Netherlands. He is a translational pulmonary researcher with a focus on elastic fiber metabolism in lung emphysema and fibrosis. He switched focus to COVID-19 research and was the first to demonstrate severe extrahepatic vitamin K deficiency in COVID‑19.

Adam Cuker

Adam Cuker

MD, MS

 

Adam Cuker is Associate Professor of Medicine and Pathology & Laboratory Medicine at the University of Pennsylvania. He received his M.D. from Yale University and completed an internship and residency in internal medicine at Brigham and Women’s Hospital and Harvard Medical School. He continued his postgraduate training at the Hospital of the University of Pennsylvania where he was a fellow in hematology/oncology. He holds a Masters degree in Translational Research from the University of Pennsylvania. He is Director of the Penn Comprehensive Hemophilia & Thrombosis Program, Assistant Director of the Penn Specialized Coagulation Laboratory, and Associate Director of the Penn-CHOP Blood Center for Patient Care and Discovery. He conducts patient-oriented research on disorders of hemostasis and thrombosis. He is Chair of the American Society of Hematology Guidelines on COVID-19 and anticoagulation.

Scientific Program

 

pro-COAG 2019 topics

  • D-Dimer thresholds in diagnosis of acute PE: implications from the YEARS study 
  • Upcoming biomarkers in coagulation: ADAMTS13, a proteolytic marker to identify CV risk and sepsis 
  • Assay challenges with emicizumab for the treatment of haemophilia A 
  • Advancements with the cobas t 711 fully automated coagulation analyser
    • Results from the first investigator-initiated study of cobas t 711: analytical performance of key coagulation assays 
    • An observational workflow comparison between cobas t 711 and other coagulation analysers
pro-COAG 2019

pro-COAG 2019

Download the write-up